[Skip to Content]
[Skip to Content Landing]
Comment & Response
May 2, 2019

Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration

Author Affiliations
  • 1Department of Ophthalmology, King’s College Hospital, School of Medicine, King’s College London, London, United Kingdom
  • 2Retina-Vitreous Associates Medical Group, Beverly Hills, California
  • 3Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
JAMA Ophthalmol. 2019;137(7):854-855. doi:10.1001/jamaophthalmol.2019.0861

To the Editor We recently reported a phase I dose-escalation study of the oral tyrosine kinase inhibitor vorolanib (previously known as X-82 [Tyrogenex]), which was used as a treatment for neovascular age-related macular degeneration (AMD).1 We have since been made aware of a 2008 report detailing 2 cases of neovascular AMD treated with oral sorafenib, which deserves mention.2 Like vorolanib, sorafenib is a multikinase inhibitor that has been used to treat cancer. It has theoretical utility as a treatment for wet AMD because it downregulates the production of vascular endothelial growth factor and platelet-derived growth factor.